Your browser doesn't support javascript.
loading
Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.
Jindal, Sonali; Pennock, Nathan D; Sun, Duanchen; Horton, Wesley; Ozaki, Michelle K; Narasimhan, Jayasri; Bartlett, Alexandra Q; Weinmann, Sheila; Goss, Paul E; Borges, Virginia F; Xia, Zheng; Schedin, Pepper.
Affiliation
  • Jindal S; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
  • Pennock ND; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Sun D; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
  • Horton W; Computational Biology Program, Oregon Health & Science University, Portland, OR, USA.
  • Ozaki MK; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
  • Narasimhan J; Computational Biology Program, Oregon Health & Science University, Portland, OR, USA.
  • Bartlett AQ; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
  • Weinmann S; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
  • Goss PE; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.
  • Borges VF; Center for Health Research, Kaiser Permanente Northwest, 3800N. Interstate Ave., Portland, OR, USA.
  • Xia Z; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA, USA.
  • Schedin P; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Nat Commun ; 12(1): 6341, 2021 11 03.
Article in En | MEDLINE | ID: mdl-34732713
ABSTRACT
Young women's breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5-10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Gene Expression Regulation, Neoplastic / Postpartum Period Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Child / Child, preschool / Female / Humans / Middle aged / Pregnancy Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2021 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Gene Expression Regulation, Neoplastic / Postpartum Period Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Child / Child, preschool / Female / Humans / Middle aged / Pregnancy Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2021 Document type: Article Affiliation country: United States